Annual EBIT
-$553.17 M
-$100.87 M-22.30%
December 31, 2022
Summary
- As of March 7, 2025, SRNE annual earnings before interest & taxes is -$553.17 million, with the most recent change of -$100.87 million (-22.30%) on December 31, 2022.
- During the last 3 years, SRNE annual EBIT has fallen by -$228.65 million (-70.45%).
- SRNE annual EBIT is now -2825.66% below its all-time high of $20.30 million, reached on December 31, 2017.
Performance
SRNE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$105.20 M
+$36.46 M+25.74%
June 30, 2023
Summary
- As of March 7, 2025, SRNE quarterly earnings before interest & taxes is -$105.20 million, with the most recent change of +$36.46 million (+25.74%) on June 30, 2023.
- Over the past year, SRNE quarterly EBIT has increased by +$36.46 million (+25.74%).
- SRNE quarterly EBIT is now -208.53% below its all-time high of $96.93 million, reached on September 30, 2017.
Performance
SRNE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$546.04 M
+$113.09 M+17.16%
June 30, 2023
Summary
- As of March 7, 2025, SRNE TTM earnings before interest & taxes is -$546.04 million, with the most recent change of +$113.09 million (+17.16%) on June 30, 2023.
- Over the past year, SRNE TTM EBIT has increased by +$113.09 million (+17.16%).
- SRNE TTM EBIT is now -1391.86% below its all-time high of $42.27 million, reached on September 30, 2017.
Performance
SRNE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
SRNE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.3% | +25.7% | +17.2% |
| 3 y3 years | -70.5% | +25.7% | +17.2% |
| 5 y5 years | -2825.7% | +25.7% | +17.2% |
SRNE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.3% | at low | -194.7% | +51.8% | -20.7% | +17.2% |
| 5 y | 5-year | -90.5% | at low | -2205.2% | +51.8% | -139.5% | +17.2% |
| alltime | all time | -2825.7% | at low | -208.5% | +51.8% | -1391.9% | +17.2% |
Sorrento Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$105.20 M(-25.7%) | -$546.04 M(-17.2%) |
| Mar 2023 | - | -$141.66 M(-32.0%) | -$659.13 M(+19.2%) |
| Dec 2022 | -$553.17 M(+22.3%) | -$208.28 M(+129.1%) | -$553.17 M(+6.4%) |
| Sep 2022 | - | -$90.91 M(-58.4%) | -$520.02 M(-4.8%) |
| Jun 2022 | - | -$218.28 M(+511.5%) | -$545.98 M(+10.7%) |
| Mar 2022 | - | -$35.70 M(-79.6%) | -$493.00 M(+9.0%) |
| Dec 2021 | -$452.30 M(+55.7%) | -$175.13 M(+49.8%) | -$452.30 M(+30.1%) |
| Sep 2021 | - | -$116.87 M(-29.3%) | -$347.75 M(+10.5%) |
| Jun 2021 | - | -$165.30 M(-3408.0%) | -$314.72 M(+38.0%) |
| Mar 2021 | - | $5.00 M(-107.1%) | -$228.03 M(-22.9%) |
| Dec 2020 | -$290.42 M(-10.5%) | -$70.58 M(-15.8%) | -$295.68 M(+2.9%) |
| Sep 2020 | - | -$83.84 M(+6.6%) | -$287.22 M(+7.2%) |
| Jun 2020 | - | -$78.62 M(+25.5%) | -$267.93 M(+7.0%) |
| Mar 2020 | - | -$62.65 M(+0.9%) | -$250.45 M(-22.8%) |
| Dec 2019 | -$324.53 M(+107.8%) | -$62.12 M(-3.8%) | -$324.53 M(+4.9%) |
| Sep 2019 | - | -$64.54 M(+5.6%) | -$309.27 M(+5.8%) |
| Jun 2019 | - | -$61.13 M(-55.3%) | -$292.42 M(+12.3%) |
| Mar 2019 | - | -$136.73 M(+191.8%) | -$260.36 M(+66.7%) |
| Dec 2018 | -$156.15 M(-869.4%) | -$46.86 M(-1.8%) | -$156.15 M(+4.9%) |
| Sep 2018 | - | -$47.70 M(+64.1%) | -$148.88 M(+3398.2%) |
| Jun 2018 | - | -$29.07 M(-10.6%) | -$4.26 M(-138.8%) |
| Mar 2018 | - | -$32.52 M(-17.9%) | $10.98 M(-46.6%) |
| Dec 2017 | $20.30 M(-131.9%) | -$39.59 M(-140.8%) | $20.56 M(-51.4%) |
| Sep 2017 | - | $96.93 M(-800.6%) | $42.27 M(-207.7%) |
| Jun 2017 | - | -$13.84 M(-39.7%) | -$39.23 M(-43.6%) |
| Mar 2017 | - | -$22.94 M(+28.3%) | -$69.59 M(+9.4%) |
| Dec 2016 | -$63.66 M(+689.1%) | -$17.89 M(-215.9%) | -$63.63 M(-4.7%) |
| Sep 2016 | - | $15.44 M(-134.9%) | -$66.74 M(+37.5%) |
| Jun 2016 | - | -$44.20 M(+160.3%) | -$48.53 M(+226.4%) |
| Mar 2016 | - | -$16.98 M(-19.1%) | -$14.87 M(+84.3%) |
| Dec 2015 | -$8.07 M(-76.8%) | -$21.00 M(-162.4%) | -$8.07 M(-353.3%) |
| Sep 2015 | - | $33.64 M(-419.4%) | $3.19 M(-108.5%) |
| Jun 2015 | - | -$10.53 M(+3.5%) | -$37.58 M(+7.3%) |
| Mar 2015 | - | -$10.18 M(+4.4%) | -$35.04 M(+0.9%) |
| Dec 2014 | -$34.73 M | -$9.74 M(+36.7%) | -$34.73 M(-3.8%) |
| Sep 2014 | - | -$7.13 M(-10.7%) | -$36.11 M(+11.8%) |
| Jun 2014 | - | -$7.99 M(-19.1%) | -$32.29 M(+11.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$9.87 M(-11.3%) | -$29.02 M(+34.0%) |
| Dec 2013 | -$21.66 M(+347.0%) | -$11.13 M(+236.6%) | -$21.66 M(+76.3%) |
| Sep 2013 | - | -$3.31 M(-29.9%) | -$12.29 M(+20.2%) |
| Jun 2013 | - | -$4.71 M(+87.7%) | -$10.22 M(+58.5%) |
| Mar 2013 | - | -$2.51 M(+43.2%) | -$6.45 M(+33.1%) |
| Dec 2012 | -$4.84 M(+49.4%) | -$1.75 M(+41.4%) | -$4.84 M(+25.7%) |
| Sep 2012 | - | -$1.24 M(+31.6%) | -$3.85 M(+16.2%) |
| Jun 2012 | - | -$943.10 K(+4.1%) | -$3.32 M(-4.2%) |
| Mar 2012 | - | -$906.10 K(+18.7%) | -$3.46 M(+6.8%) |
| Dec 2011 | -$3.24 M(+78.9%) | -$763.30 K(+8.5%) | -$3.24 M(+21.5%) |
| Sep 2011 | - | -$703.70 K(-35.4%) | -$2.67 M(+10.7%) |
| Jun 2011 | - | -$1.09 M(+58.8%) | -$2.41 M(+27.0%) |
| Mar 2011 | - | -$686.10 K(+263.6%) | -$1.90 M(+4.7%) |
| Dec 2010 | -$1.81 M(+89.9%) | -$188.70 K(-57.6%) | -$1.81 M(-21.7%) |
| Sep 2010 | - | -$445.50 K(-22.7%) | -$2.31 M(+9.8%) |
| Jun 2010 | - | -$576.50 K(-4.1%) | -$2.11 M(+35.4%) |
| Mar 2010 | - | -$601.40 K(-12.8%) | -$1.56 M(+63.0%) |
| Dec 2009 | -$954.10 K(+3612.5%) | -$689.90 K(+189.0%) | -$954.20 K(+555.4%) |
| Sep 2009 | - | -$238.70 K(+832.4%) | -$145.60 K(+345.3%) |
| Jun 2009 | - | -$25.60 K(-121.6%) | -$32.70 K(+27.2%) |
| Dec 2008 | -$25.70 K(-89.3%) | $118.70 K(-194.4%) | -$25.70 K(-83.1%) |
| Sep 2008 | - | -$125.80 K(+2229.6%) | -$151.80 K(+314.8%) |
| Jun 2008 | - | -$5400.00(-59.1%) | -$36.60 K(-16.4%) |
| Mar 2008 | - | -$13.20 K(+78.4%) | -$43.80 K(-81.8%) |
| Dec 2007 | -$240.60 K(-45.2%) | -$7400.00(-30.2%) | -$240.50 K(+3.2%) |
| Sep 2007 | - | -$10.60 K(-15.9%) | -$233.10 K(+4.8%) |
| Jun 2007 | - | -$12.60 K(-94.0%) | -$222.50 K(+6.0%) |
| Mar 2007 | - | -$209.90 K(-31.7%) | -$209.90 K(-31.9%) |
| Dec 2006 | -$439.30 K(+42.6%) | - | - |
| Dec 2005 | -$308.00 K(>+9900.0%) | -$307.50 K(>+9900.0%) | -$308.10 K(>+9900.0%) |
| Sep 2005 | - | -$200.00(0.0%) | -$800.00(0.0%) |
| Jun 2005 | - | -$200.00(0.0%) | -$800.00(0.0%) |
| Mar 2005 | - | -$200.00(0.0%) | -$800.00(0.0%) |
| Dec 2004 | -$800.00(0.0%) | -$200.00(0.0%) | -$800.00(+33.3%) |
| Sep 2004 | - | -$200.00(0.0%) | -$600.00(+50.0%) |
| Jun 2004 | - | -$200.00(0.0%) | -$400.00(+100.0%) |
| Mar 2004 | - | -$200.00 | -$200.00 |
| Dec 2003 | -$800.00 | - | - |
FAQ
- What is Sorrento Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual EBIT year-on-year change?
- What is Sorrento Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly EBIT year-on-year change?
- What is Sorrento Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM EBIT year-on-year change?
What is Sorrento Therapeutics annual earnings before interest & taxes?
The current annual EBIT of SRNE is -$553.17 M
What is the all time high annual EBIT for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual earnings before interest & taxes is $20.30 M
What is Sorrento Therapeutics annual EBIT year-on-year change?
Over the past year, SRNE annual earnings before interest & taxes has changed by -$100.87 M (-22.30%)
What is Sorrento Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of SRNE is -$105.20 M
What is the all time high quarterly EBIT for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly earnings before interest & taxes is $96.93 M
What is Sorrento Therapeutics quarterly EBIT year-on-year change?
Over the past year, SRNE quarterly earnings before interest & taxes has changed by +$36.46 M (+25.74%)
What is Sorrento Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of SRNE is -$546.04 M
What is the all time high TTM EBIT for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM earnings before interest & taxes is $42.27 M
What is Sorrento Therapeutics TTM EBIT year-on-year change?
Over the past year, SRNE TTM earnings before interest & taxes has changed by +$113.09 M (+17.16%)